ISO 10993 Updates: A Manufacturer's Guide to Biocompatibility

## ISO 10993 Updates: A Manufacturer's Guide to Biocompatibility As the medical device industry adapts to significant updates to the ISO 10993 series of standards, manufacturers must transition from a simple checklist-based testing approach to a comprehensive, risk-based biological evaluation strategy. This evolution, driven by a deeper understanding of material science and toxicology, requires a proactive and strategic plan to ensure continued regulatory compliance with bodies like the FDA and EU Notified Bodies. A successful transition involves more than just commissioning new tests; it demands a fundamental update to a company's overall biological risk assessment, documentation, and lifecycle management processes. The core of this shift is moving the focus from a default "test everything" mindset to a more intelligent, evidence-based approach. This involves thoroughly understanding a device's materials through chemical characterization and using that data to conduct a toxicological risk assessment. This modern methodology, when executed correctly, can provide a robust justification for a device's safety, often reducing the need for traditional, and sometimes lengthy and costly, animal testing. For both new and legacy devices, adapting to these updated principles is not just a compliance exercise—it is a critical component of modern product development and risk management. ### Key Points * **Risk-Based Approach is Paramount:** The updated ISO 10993-1 emphasizes a comprehensive Biological Evaluation Plan (BEP) based on risk management principles, not a fixed menu of tests. The evaluation must consider the device's materials, manufacturing processes, clinical use, and potential leachables. * **Chemical Characterization is Foundational:** ISO 10993-18 (Chemical Characterization) is now a central starting point. Identifying and quantifying chemical constituents that may leach from a device is critical for informing the toxicological risk assessment. * **Toxicological Assessment Can Reduce Animal Testing:** A robust toxicological risk assessment, per ISO 10993-17, uses chemical characterization data to evaluate the potential health risks of leachables. A well-justified assessment can often conclude that the risk is negligible, potentially eliminating the need for certain in vivo biocompatibility tests. * **Legacy Devices Require a Gap Analysis:** Manufacturers cannot assume that prior testing on existing devices is sufficient. A documented gap analysis is necessary to compare legacy data against the current versions of the standards and justify why the data remains relevant, or to identify what new testing or analysis is required. * **Documentation is a Narrative, Not a Data Dump:** The Biological Evaluation Report (BER) must be a comprehensive, standalone document that tells the complete story of the device's biological safety. It should synthesize all information—from material data and chemical analysis to testing results and risk assessments—into a clear, logical argument. --- ### ## Evolving the Biological Evaluation Plan (BEP) to a Living Document The Biological Evaluation Plan (BEP) is the strategic foundation of any biocompatibility program. Under the new paradigm, it is no longer a static pre-testing plan but a dynamic document that guides the entire evaluation process. It must be authored early in the device development lifecycle and updated as new information becomes available. A comprehensive BEP should include: 1. **Device Description and Intended Use:** A detailed description of the device, its components, materials of construction, and its intended clinical application, including the nature and duration of body contact. 2. **Material Characterization:** A complete inventory of all materials with patient contact, including processing aids, colorants, and manufacturing residuals. This section should reference material supplier data and any known chemical information. 3. **Risk Analysis of Body Contact:** An analysis based on ISO 10993-1, identifying the relevant biological endpoints for evaluation (e.g., cytotoxicity, sensitization, systemic toxicity) based on the device's categorization. 4. **Information Gathering and Literature Review:** A summary of existing data, including literature on the known biocompatibility of the device's materials, clinical history of similar devices, and any previously conducted testing. 5. **Proposed Evaluation Strategy:** A clear plan outlining the specific testing and analysis to be performed. Crucially, this section must include a strong rationale for the proposed approach. If chemical characterization and toxicological risk assessment will be used to obviate certain biological tests, that justification must be explicitly stated here. 6. **Criteria for Success:** Pre-defined acceptance criteria for all planned tests and assessments. ### ## The Central Role of Chemical and Toxicological Assessment The most significant shift in the ISO 10993 series is the increased emphasis on understanding what chemical substances a patient may be exposed to and assessing the associated toxicological risk. #### ### ISO 10993-18: Chemical Characterization The goal of chemical characterization is to identify and quantify the substances that can be released from a medical device during its clinical use. This typically involves extractables and leachables (E&L) studies. An extractables study uses aggressive solvents and conditions to create a "worst-case" profile of what *could* be released. A leachables study uses more clinically relevant conditions to simulate what is *likely* to be released during actual patient use. This data provides the chemical "fingerprint" of the device. #### ### ISO 10993-17: Toxicological Risk Assessment Once the chemical fingerprint is known, a toxicological risk assessment evaluates the potential for patient harm. A qualified toxicologist assesses each identified chemical constituent by: * **Hazard Identification:** Determining the potential adverse health effects of the substance. * **Dose-Response Assessment:** Establishing the relationship between the dose of the substance and the likelihood of an adverse effect. This often involves identifying a Tolerable Intake (TI) or Tolerable Exposure (TE) level from scientific literature. * **Exposure Assessment:** Calculating the patient's worst-case exposure to the substance from the device based on the E&L data. * **Risk Characterization:** Comparing the calculated patient exposure to the tolerable exposure level to determine a Margin of Safety (MOS). If the MOS is sufficiently large, the risk is generally considered acceptable. A well-executed toxicological risk assessment can provide powerful evidence to justify that further biological testing for certain endpoints (like sub-chronic or chronic toxicity) is unnecessary. ### ## Managing Legacy Devices: A Framework for Gap Analysis For devices already on the market, manufacturers must proactively assess whether their existing biocompatibility data meets current regulatory expectations. A structured gap analysis is the best practice for this evaluation. **Step-by-Step Gap Analysis Process:** 1. **Inventory Existing Data:** Compile all historical biocompatibility test reports, material specifications, and manufacturing process descriptions for the legacy device. 2. **Review Current Standards:** Compare the test methods, parameters, and acceptance criteria from the historical reports against the requirements of the current versions of the relevant ISO 10993 standards. 3. **Assess Changes Over Time:** Document any changes since the original testing was performed. This includes changes in material suppliers, manufacturing processes (e.g., sterilization methods, cleaning agents), or the device's shelf life. Even seemingly minor changes can impact the device's biological safety profile. 4. **Evaluate Material Information:** Determine if the existing material information is sufficient for a modern chemical and toxicological risk assessment. Often, older submissions lacked the detailed chemical characterization data required today. 5. **Document Findings and Create an Action Plan:** The output should be a formal gap analysis report that clearly justifies why existing data is still sufficient or, if gaps are identified, outlines a plan to address them. This plan might include targeted chemical characterization, a new toxicological risk assessment, or specific biological tests. --- ### ## Scenarios: Applying the New Principles #### ### Scenario 1: A Legacy Orthopedic Implant with a New Sterilization Method A company changes its sterilization method for a long-marketed titanium implant from gamma irradiation to vaporized hydrogen peroxide. * **What Regulators Will Scrutinize:** Regulators will focus on whether the new sterilization method introduces new chemical residues or alters the device surface in a way that could affect its biological response. The original biocompatibility data, conducted with the gamma-sterilized device, may no longer be fully relevant. * **Strategic Approach:** 1. **Update the BEP:** The BEP must be revised to identify the potential risks associated with the new sterilization method, specifically focusing on potential residuals. 2. **Conduct Targeted Chemical Characterization:** Perform an extractables study on the newly sterilized device to identify and quantify any hydrogen peroxide residuals or other process-related chemicals. 3. **Perform a Toxicological Risk Assessment:** A toxicologist will assess the risk of the identified residuals. If the levels are well below established safety limits, this assessment may be sufficient. 4. **Consider Limited Biological Testing:** Depending on the risk assessment, limited testing (e.g., cytotoxicity) might be prudent to confirm that the new process does not induce a toxic response. A full slate of testing is likely unnecessary if the risk assessment is robust. #### ### Scenario 2: A New Device with a Novel Resorbable Polymer A startup is developing a new vascular stent made from a novel, proprietary resorbable polymer. * **What Regulators Will Scrutinize:** For a novel material, especially one that degrades in the body, the scrutiny will be immense. Regulators will expect a complete characterization of the polymer and all its degradation products over the full absorption timeline. * **Strategic Approach:** 1. **Develop an Exhaustive BEP:** The BEP must outline a multi-stage evaluation plan covering the device from implantation through complete absorption. This will involve leveraging ISO 10993 parts -9, -13, -14, -15, and -16 for degradation and toxicokinetics. 2. **In-Depth Chemical and Material Characterization:** This goes beyond standard E&L. It must include studies to identify all substances released as the polymer breaks down in a simulated physiological environment over time. 3. **Comprehensive Toxicological Risk Assessment:** The risk assessment must cover the parent polymer *and* all identified degradation products. 4. **Staged Biological Testing:** A full battery of biological tests will likely be unavoidable. The testing will need to be timed to assess the biological response at different stages of material degradation. 5. **Early FDA Engagement:** This is a prime candidate for a Q-Submission to discuss the proposed biocompatibility evaluation strategy with the FDA *before* initiating this long and expensive process. ### ## Strategic Considerations and the Role of Q-Submission Proactive engagement with regulatory authorities is a powerful risk mitigation tool. For devices involving novel materials, challenging patient populations, or complex manufacturing processes, using the FDA's Q-Submission program to gain feedback on a proposed BEP is highly recommended. Presenting a well-developed BEP, including the rationale for the testing and analysis strategy, allows sponsors to get agency alignment early. This can prevent costly missteps, such as performing the wrong tests or generating insufficient data, and can significantly de-risk the final submission review process. ### ## Finding and Comparing Biocompatibility Testing Services Providers Choosing the right partner for biocompatibility evaluation is as critical as the plan itself. A qualified provider is not just a testing laboratory but a strategic partner who can provide guidance on study design, interpretation of results, and regulatory expectations. When selecting a provider, sponsors should look for: * **Accreditation and Compliance:** The facility must be ISO/IEC 17025 accredited and operate under Good Laboratory Practice (GLP) principles as required by 21 CFR Part 58. * **Integrated Services:** A provider that offers in-house chemistry, toxicology, and biological testing services can ensure a seamless and efficient evaluation process. This integration is crucial for the modern risk-based approach. * **Regulatory Experience:** The provider should have extensive experience with FDA, EU MDR, and other global regulatory submissions and be up-to-date on the latest interpretations of the ISO 10993 standards. * **Technical Expertise:** Look for on-staff experts (e.g., PhD toxicologists, analytical chemists) who can help design studies and justify the scientific rationale in the final BEP and BER. Comparing providers based on their full range of expertise, not just on a price list for individual tests, is essential for a successful outcome. **To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free.** ### ## Key FDA References * **Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"**: This is the key FDA guidance document outlining the agency's expectations for a risk-based biocompatibility approach. * **FDA's Q-Submission Program Guidance**: This guidance details the processes for formally requesting feedback from the FDA on regulatory, testing, and clinical strategies prior to a formal marketing submission. * **21 CFR Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies**: These regulations set the standards for conducting nonclinical safety studies, including most biocompatibility tests. --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*